Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Camostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 5/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.90 |
| ▸ | PRSS1 | P07477 | 12/20 | 1.00 |
| ▸ | KLK1 | P06870 | 4/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.90 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.90 |
| ▸ | HGFAC | Q04756 | 3/20 | 0.90 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.90 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.90 |
| ▸ | HPN | P05981 | 1/20 | 0.90 |
| ▸ | CTSL | P07711 | 1/20 | 0.90 |
| ▸ | CNR1 | P21554 | 1/20 | 0.90 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.90 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.90 |
| ▸ | ACR | P10323 | 7/20 | 0.61 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.58 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camostat SCHEMBL125270 | 0.95 | PRSS1 (1.00) | PRSS1F2KLK1PRSS2PRSS3 | |
| Camostat SCHEMBL871583 | 0.83 | PRSS1 (0.72) | PRSS1F2KLK1PRSS2PRSS3 | |
| SCHEMBL15571972 | 0.83 | PRSS1 (0.70) | PRSS1F2KLK1PRSS2PRSS3 | |
| SCHEMBL1649708 | 0.82 | PRSS1 (1.00) | PRSS1F2KLK1PRSS2PRSS3 | |
| SCHEMBL21920058 | 0.81 | PRSS1 (0.74) | PRSS1F2KLK1PRSS2PRSS3 | |
| SCHEMBL4752946 | 0.79 | PRSS1 (0.66) | PRSS1F2KLK1PRSS2PRSS3 | |
| SCHEMBL20008640 | 0.79 | PRSS1 (0.68) | PRSS1F2KLK1PRSS2PRSS3 | |
| Camostat SCHEMBL125269 | 0.79 | PRSS1 (0.68) | PRSS1F2KLK1PRSS2PRSS3 | |
| SCHEMBL13283061 | 0.79 | PRSS1 (0.68) | PRSS1F2KLK1PRSS2PRSS3 | |
| Camostat SCHEMBL2782237 | 0.78 | PRSS1 (0.67) | PRSS1F2KLK1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| WO-2024187239-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4189397-A2 | METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT | Sciomics GmbH (DE) | 2023-06-07 | — | — | EP | claimed |
| CN-116194114-A | Cathepsin inhibitors for preventing or treating viral infections | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230158259-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | TOPELIA AUST LIMITED (652 771 670) (AU) | 2023-05-25 | — | — | US | claimed |
| CN-115955965-A | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | 拓比利亚欧斯特有限公司 | 2023-04-11 | — | — | CN | claimed |
| EP-4138832-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | Topelia Aust Limited (AU) | 2023-03-01 | — | — | EP | claimed |
| EP-4125919-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-02-08 | — | — | EP | claimed |
| WO-2022028917-A2 | METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT | SCIOMICS GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | disclosed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | disclosed |
| US-12502381-B2 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2025-12-23 | — | — | US | disclosed |
| CN-117695284-B | Treatment of coronavirus infection | 红山生物医药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-06-12 | — | — | US | disclosed |
| WO-2022066823-A1 | CORONAVIRUS REPLICONS FOR ANTIVIRAL SCREENING AND TESTING | MERCK SHARP & DOHME CORP. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11278602-B2 | Medicine for Covid-19 and treatment | Therapeutica Borealis Oy (FI) | 2022-03-22 | — | — | US | disclosed |
| WO-2022049177-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL (DE) | 2022-03-10 | — | — | WO | disclosed |
| EP-3964207-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | Christian-Albrechts-Universität zu Kiel (DE) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022028917-A2 | METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT | SCIOMICS GMBH (DE) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | TPMT, ADH1C, ADH1A | F2 1213/4885ADRA1A 3293/4885PRSS1 1209/4885 |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | ACE, MAVS, SARS1 | F2 828/4885ADRA1A 2150/4885PRSS1 281/4885 |
| US-12502381-B2 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | F2 129/4885ADRA1A 3326/4885PRSS1 1/4885 |
| US-11278602-B2 | Medicine for Covid-19 and treatment | ACE2, HAVCR2, TMPRSS2 | F2 2277/4885ADRA1A 2039/4885PRSS1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.